Rapamycin

• Catalog Number: ACM53123889
• Product Name: Rapamycin
• CAS: 53123-88-9
• Category: Inhibitors
• Description: Rapamycin (Sirolimus; AY 22989) is a potent and specific mTOR inhibitor with an IC50 of 0.1 nM in HEK293 cells. Rapamycin binds to FKBP12 and specifically acts as an allosteric inhibitor of mTORC1. Rapamycin is an autophagy activator, an immunosuppressant.
• Synonyms: 23,27-Epoxy-3H-pyrido[2,1-c][1,4]oxaazacyclohentriacontine solution
• IUPAC Name: (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.04,9]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone
• Molecular Weight: 914.18
• Molecular Formula: C51H79NO13
• Canonical SMILES: C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC
• InChI: InChI=1S/C51H79NO13/c1-30-16-12-11-13-17-31(2)42(61-8)28-38-21-19-36(7)51(60,65-38)48(57)49(58)52-23-15-14-18-39(52)50(59)64-43(33(4)26-37-20-22-40(53)44(27-37)62-9)29-41(54)32(3)25-35(6)46(56)47(63-10)45(55)34(5)24-30/h11-13,16-17,25,30,32-34,36-40,42-44,46-47,53,56,60H,14-15,18-24,26-29H2,1-10H3/b13-11+,16-12+,31-17+,35-25+/t30-,32-,33-,34-,36-,37+,38+,39+,40-,42+,43+,44-,46-,47+,51-/m1/s1
• InChI Key: QFJCIRLUMZQUOT-HPLJOQBZSA-N
• Boiling Point: 800 °C
• Melting Point: 183-185 °C
• Density: 1.035 g/ml
• Appearance: Powder
• pKa: 10.40±0.70

Custom Q&A

What is the molecular formula of Rapamycin?

The molecular formula of Rapamycin is C51H79NO13.

What is the molecular weight of Rapamycin?

The molecular weight of Rapamycin is 914.2 g/mol.

What is the PubChem CID of Rapamycin?

The PubChem CID of Rapamycin is 5284616.

What is the synonym for Rapamycin?

The synonym for Rapamycin is (-)-Rapamycin.

What is the primary mechanism of action of Rapamycin?

The primary mechanism of action of Rapamycin is the inhibition of the mammalian target of rapamycin (mTOR).

What are the therapeutic targets of Rapamycin?

The therapeutic targets of Rapamycin include organ rejection in patients receiving renal transplants, maintenance therapy with corticosteroids, treatment of lymphangioleiomyomatosis, and the treatment of malignant perivascular epithelioid cell tumor (PEComa).

When was Rapamycin first approved by the FDA?

Rapamycin was first approved by the FDA in 1999 for the prophylaxis of organ rejection in patients aged 13 years and older receiving renal transplants.

What is the IUPAC name of Rapamycin?

The IUPAC name of Rapamycin is (1R,9S,12S,15R,16E,18R,19R,21R,23S,24E,26E,28E,30S,32S,35R)-1,18-dihydroxy-12-[(2R)-1-[(1S,3R,4R)-4-hydroxy-3-methoxycyclohexyl]propan-2-yl]-19,30-dimethoxy-15,17,21,23,29,35-hexamethyl-11,36-dioxa-4-azatricyclo[30.3.1.0 4,9 ]hexatriaconta-16,24,26,28-tetraene-2,3,10,14,20-pentone.

What is the pharmacological effect of Rapamycin?

The pharmacological effect of Rapamycin is decreased immunologic activity.

What are the different names and roles of Rapamycin?

Rapamycin is also known as Sirolimus and has various roles such as an antibiotic, immunosuppressive agent, antineoplastic agent, mTOR inhibitor, antibacterial drug, anticoronaviral agent, and geroprotector.